Gland Pharma planning to invest Rs 400 crore to expand Telangana’s existing facility

21 Feb 2023 Evaluate

Gland Pharma is planning to invest Rs 400 crore to create additional capabilities in its existing facility at Genome Valley in Telangana to manufacture biologicals, biosimilar, antibodies and recombinant Insulin.

The expanded facility will have employment generation potential of more than 500 numbers of qualified, skilled and semi-skilled workforce to be recruited, mostly from the nearby places. The company had established their biopharmaceutical facility in February last year at Genome Valley with an investment of Rs 300 crore to manufacture vaccines, biologicals, biosimilar, antibodies and others. The expanded site is envisaged to meet the national and international regulations to be followed in the manufacturing of the biological products as applicable and shall be built under the GMP guidelines applicable for the respective product lines.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1681.95 -39.70 (-2.31%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×